Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Peri- or postmenopausal women~* DSM-5 criteria for Insomnia disorder, with onset of symptoms attributed to hot flashes~* Some awakenings co-occur with a hot flash~* Score on the Insomnia Severity Index (ISI) measure ≥15~* Hot flashes present, including at night~Exclusion Criteria:~* Diagnosis of other primary sleep disorders~* Shift workers~* Current or expected use of hypnotic medications~* Current major depressive episode~* Lifetime history of bipolar disorder, psychosis, or other serious mental health problem~* Current alcohol/substance use disorder~* Obesity~* Renal or hepatic disease~* Pregnancy or breastfeeding~* Recent malignancy~* Recent surgery~* Neurological disorder or cardiovascular disease raising safety concerns~* Medical instability considered to interfere with study procedures~* Concomitant medications with drug interaction or co-administration concerns~* Contraindications or allergic responses to suvorexant~* Recent or planned travel across time zones~* Excessive coffee or cigarette use

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- suvorexant (Type: EXPERIMENTAL): suvorexant 10-20 mg taken at bedtime for four weeks
- placebo (Type: PLACEBO_COMPARATOR): placebo taken at bedtime for four weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).